GMAB

Rating neutralAI Memo

Genmab A/S

As of 2026-05-28/Confidence low/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-28 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

low

Horizon

6‑12m

Key catalyst

Q1 2026 results kept royalty growth and guidance intact • 2026-05-07

Expected move: +40%

Biggest risk

The stock depends on a concentrated royalty stream and a few late-stage oncology assets; rising R&D, SG&A, and integration charges mean execution risk stays high if launch timing or readouts slip.

Invalidation

Break below $21 or thesis failure.

What would change my mind?

Genmab is still growing on the back of DARZALEX/Kesimpta royalties and EPKINLY sales, while the late-stage Rina-S and petosemtamab programs plus ASCO/EHA visibility keep multiple shots on goal alive.

Research note

Recommendation

neutral

Confidence

low

As of

2026-05-28

Base target

$37

p=45%

Bull target

$44

p=25%

Bear target

$21

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Rina-S and petosemtamab remain the main longer-dated rerating path
Genmab is still growing on the back of DARZALEX/Kesimpta royalties and EPKINLY sales, while the late-stage Rina-S and petosemtamab programs plus ASCO/EHA visibility keep multiple shots on goal alive.
At $26.71, the shares trade well below the packet's median/mean analyst target of $36.86, implying roughly 38% upside; however, the packet lacks current analyst revision counts, so the valuation gap is only modest evidence rather than a strong rerating signal.

BearKey bullets

Concentration risk remains high because current growth is still heavily reliant on DARZALEX and Kesimpta royalties plus EPKINLY uptake.
Management maintained 2026 guidance, but any slip in launch timing, label expansion, or clinical readout cadence could weaken sentiment quickly.
Operating expenses and acquisition/integration charges rose materially in Q1, and further spend on launch readiness could pressure margins before new products contribute.

WatchKey bullets

Q1 2026 results kept royalty growth and guidance intact

Summary

High-level snapshot

Recommendation

neutral

Model confidence

low

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $37 (p=45%)

Bull/Bear spread: +67% / -20%

Vs latest close: Bull +67% · Base +40% · Bear -20%

Scenario probabilities

Bull Target: $44 (p=25%)Base Target: $37 (p=45%)Bear Target: $21 (p=30%)

Commentary

Primary-source evidence points to a credible but cautious monitor: Q1 showed strong royalty-led growth and guidance was maintained, yet forward visibility still hinges on a few oncology readouts and launch preparations. Analyst revision data are unavailable in the packet, and the post-earnings market response appears mixed in secondary coverage, so confidence stays moderate-to-low rather than bullish.

As of 2026-05-28 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Genmab is still growing on the back of DARZALEX/Kesimpta royalties and EPKINLY sales, while the late-stage Rina-S and petosemtamab programs plus ASCO/EHA visibility keep multiple shots on goal alive.

Bear Case

The stock depends on a concentrated royalty stream and a few late-stage oncology assets; rising R&D, SG&A, and integration charges mean execution risk stays high if launch timing or readouts slip.

Drivers

Scannable catalysts and supporting factors

Rina-S and petosemtamab remain the main longer-dated rerating path

Scenarios

Bull Target (Scenario probability)

$44 / p=25% prob

Base Target (Scenario probability)

$37 / p=45% prob

Bear Target (Scenario probability)

$21 / p=30% prob

Price $26 as of 2026-05-29

Nearest Scenario: Bear (∆ 20%)

Targets vs latest close: Bull +67% · Base +40% · Bear -20%

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-05-07
Q1 2026 results kept royalty growth and guidance intact
Genmab reported Q1 revenue of $896M, up 25% year over year, driven mainly by higher DARZALEX and Kesimpta royalties plus higher EPKINLY sales; operating expenses rose as the company kept investing in Rina-S and petosemtamab, and management maintained 2026 guidance. [#10Q-GMAB-2026Q1]
Prob 70.00% • Move 4.00% • Priced-in 65.00%
EVENT2026-05-29
ASCO/EHA 2026 oncology data slate keeps epcoritamab in focus
Genmab said 23 abstracts will be presented or published at ASCO and EHA 2026, including 20 abstracts evaluating epcoritamab, so the near-term readthrough is concentrated on the blood-cancer franchise rather than a broad pipeline reset. [#IR-GMAB-ASCO2026]
Prob 55.00% • Move 5.00% • Priced-in 45.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Rina-S and petosemtamab remain the main longer-dated rerating path
2026-10-31
Genmab is still funding launch readiness for Rina-S and petosemtamab, and official Genmab releases show Rina-S ovarian-cancer safety/tolerability updates plus an earlier FDA breakthrough designation in endometrial cancer, keeping these programs central to the longer-term rerating case. [#PR-GMAB-RinaS-2026-04-13]
Prob 40% • Move 6% • Priced-in 35%

Risks

Concentration risk remains high because current growth is still heavily reliant on DARZALEX and Kesimpta royalties plus EPKINLY uptake.
Management maintained 2026 guidance, but any slip in launch timing, label expansion, or clinical readout cadence could weaken sentiment quickly.
Operating expenses and acquisition/integration charges rose materially in Q1, and further spend on launch readiness could pressure margins before new products contribute.
Rina-S, petosemtamab, and epcoritamab remain execution-sensitive oncology assets, so clinical or regulatory disappointment would hit the rerating case.

Peers

Symbol	Summary
ASND	Ascendis is a smaller Nordic biopharma with an approved product and pipeline, making it a useful size-and-execution peer, though its therapeutic mix is less oncology-heavy than Genmab's.
GILD	Gilead offers a broader oncology/biopharma benchmark with a much larger commercial base; it is useful for comparing product-mix durability, but Genmab's royalty model is more concentrated.
NBIX	Neurocrine provides a profitable specialty-biopharma comparison on commercial discipline and pipeline execution, but its business is more neuroscience-centric than Genmab's oncology focus.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-05-28

AI Stock Memo: GMAB - Genmab A/S - RankAlpha